Kaifu (Suzhou) Biomedicine Co., Ltd.

Primary purpose: To evaluate the safety and tolerability of KF-0210 in patients with advanced solid tumors; To evaluate the dose-limiting toxicity (DLT) of KF-0210 in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) or maximum dose (MAD), and preliminarily determine the recommended dose (RP2D) for Phase II clinical trials. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of KF-0210 in patients with advanced solid tumors; To explore the pharmacodynamic characteristics and biomarkers of KF-0210 in patients with advanced solid tumors; To evaluate the preliminary anti-tumor activity of KF-0210 in patients with advanced solid tumors.

Primary purpose: Evaluate the safety and tolerability of multiple doses of KBP-2205 in subjects with advanced malignant solid tumors Determine the maximum tolerated dose (MTD) or the highest dose (MAD) Provide a basis for the Phase II recommended dose (RP2D) Secondary purpose: Characterize the pharmacokinetic (PK) characteristics of multiple doses of KBP-2205 in subjects with advanced malignant solid tumors Observe the preliminary anti-tumor activity of KBP-2205 in the treatment of advanced solid tumors Study the effect of KBP-2205 on the ECG QTc interval to provide a basis for the subsequent evaluation of potential cardiac toxicity Exploratory purpose: Study the relationship between the expression level of biomarkers and the anti-tumor activity of KBP-2205 to provide a basis for the selection of biomarkers in subsequent clinical trials Study the relationship between KBP-2205 exposure and selected study endpoints (such as safety and efficacy)